NASDAQ : FHTX
Foghorn Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.09 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 124.12M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 126.49M |
| Enterprise Value | 2.01M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 59.39M |
| Shares Outstanding | 59.39M |
| Shares Change (YoY) | +5.91% |
| Shares Change (QoQ) | +1.57% |
| Owned by Insiders (%) | 7.40% |
| Owned by Institutions (%) | 37.35% |
| Float | 25.58M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.44 |
| Forward PS | 7.15 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.36 |
| Quick Ratio | 3.31 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -19.92% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -44.81% |
| Weighted Average Cost of Capital (WACC) | 15.52% |
| Revenue Per Employee | $346,594 |
| Profits Per Employee | -$609,236 |
| Employee Count | 106 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 3.01 |
| 52-Week Price Change | -51.70% |
| 50-Day Moving Average | 3.51 |
| 200-Day Moving Average | 4.69 |
| Relative Strength Index (RSI) | 33.48 |
| Average Volume (20 Days) | 687,791 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.46M |
| Short Previous Month | 2.15M |
| Short % of Shares Out | 4.13% |
| Short % of Float | 9.60% |
| Short Ratio (days to cover) | 1.91 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 36.74M |
| Gross Profit | -42.09M |
| Operating Income | -68.48M |
| Pretax Income | -64.58M |
| Net Income | -64.58M |
| EBITDA | -66.35M |
| EBIT | -68.48M |
| Loss Per Share | -$0.97 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 167.58M |
| Total Debt | 43.10M |
| Net Cash | 124.48M |
| Net Cash Per Share | $2.10 |
| Equity (Book Value) | -81.04M |
| Book Value Per Share | -1.38 |
| Working Capital | 119.47M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -84.24M |
| Capital Expenditures | -50,000 |
| Depreciation & Amortization | 2.12M |
| Net Borrowing | n/a |
| Free Cash Flow | -84.29M |
| FCF Per Share | -$1.42 |
Margins
| Measure | Value |
|---|
| Gross Margin | -114.57% |
| Operating Margin | -186.38% |
| Pretax Margin | -175.78% |
| Profit Margin | -175.78% |
| EBITDA Margin | -180.61% |
| EBIT Margin | -186.38% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -5.91% |
| Shareholder Yield | -5.91% |
| Earnings Yield | -45.55% |
| FCF Yield | -66.64% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $4.17 |
| Price Target Difference | 95.63% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | -38.67% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -4.17 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |